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Melanoma is the most dangerous type of skin cancer and
one of the fastest growing cancers in the USA. Immu-
notherapy, by enhancing patient’s immune system, has
become an attractive approach for melanoma treatment
due to the rapid drug resistance to chemotherapy. B cells
are a heterogeneous cell population in the host immune
system functionally as antibody-producers, antigen-pre-
senting cells or regulatory cells. In the tumor microenvir-
onment, B cells are among the heavy tumor-infiltrating
immune cells. But B cell’s role in anti-tumor immunity
remains controversial. Our lab has recently developed a
novel GM-CSF and IL-4 fusion cytokine named GIFT4
(GMCSF and IL4 Fusion Transgene). This technology
builds upon the successful development of “fusokine” plat-
form [GIFT15] (Nature Medicine, 2009, 15: 1038-45). We
discovered GIFT4 possess novel gain-of-function of
immune activities, elicits robust B cell response and conse-
quent killer T cell immunity against melanoma. GIFT4
protein has potent immune signaling activities, induces
hyper-phosphorylation of STAT1, 3 and 5 in B cells, and
reprograms B cells from melanoma patients into CD40
+CD80+ CD83+CD86+ antigen-presenting cells profiled by
flow cytometry. Luminex assay reveals that GIFT4-B cells
secrete substantial amount of IL-2, innate cytokines IL-6
and GM-CSF, chemokines CCL2, CCL3, CCL4 and CCL5,
and adhesion molecule ICAM-1, but not IL-10 and IFN-
g. Those GIFT4-B cells robustly promote sustained ex
vivo expansion of tumor-killing T cells that are IFN-g+,
NKG2D+ Granzyme B+ and granulysin+, and produce Fas
ligand and TRAIL. Moreover, human GIFT4-B cell
licensed cytotoxic T cells kill human melanoma cells in in
vitro and in NSG immune deficient mice. We expect that
GIFT4, as an anti-melanoma agent, will provide a novel
strategy and opens a new avenue for human B cell-based
immunotherapy against melanoma. We propose that
GIFT4-B cells from melanoma patients could serve as a
potential immunotherapeutic agent for personalized mela-
noma cell immunotherapy.
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